Back to Search Start Over

Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19

Authors :
Martijn Zoodsma
Aline H. de Nooijer
Inge Grondman
Manoj Kumar Gupta
Agnes Bonifacius
Valerie A. C. M. Koeken
Emma Kooistra
Gizem Kilic
Ozlem Bulut
Nina Gödecke
Nico Janssen
Matthijs Kox
Jorge Domínguez-Andrés
Adriaan J. van Gammeren
Anton A. M. Ermens
Andre J. A. M. van der Ven
Peter Pickkers
Rainer Blasczyk
Georg M. N. Behrens
Frank L. van de Veerdonk
Leo A. B. Joosten
Cheng-Jian Xu
Britta Eiz-Vesper
Mihai G. Netea
Yang Li
Source :
Frontiers in Immunology, Vol 13 (2022)
Publication Year :
2022
Publisher :
Frontiers Media S.A., 2022.

Abstract

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic is caused by the highly infectious Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There is an urgent need for biomarkers that will help in better stratification of patients and contribute to personalized treatments. We performed targeted proteomics using the Olink platform and systematically investigated protein concentrations in 350 hospitalized COVID-19 patients, 186 post-COVID-19 individuals, and 61 healthy individuals from 3 independent cohorts. Results revealed a signature of acute SARS-CoV-2 infection, which is represented by inflammatory biomarkers, chemokines and complement-related factors. Furthermore, the circulating proteome is still significantly affected in post-COVID-19 samples several weeks after infection. Post-COVID-19 individuals are characterized by upregulation of mediators of the tumor necrosis (TNF)-α signaling pathways and proteins related to transforming growth factor (TGF)-ß. In addition, the circulating proteome is able to differentiate between patients with different COVID-19 disease severities, and is associated with the time after infection. These results provide important insights into changes induced by SARS-CoV-2 infection at the proteomic level by integrating several cohorts to obtain a large disease spectrum, including variation in disease severity and time after infection. These findings could guide the development of host-directed therapy in COVID-19.

Details

Language :
English
ISSN :
16643224
Volume :
13
Database :
Directory of Open Access Journals
Journal :
Frontiers in Immunology
Publication Type :
Academic Journal
Accession number :
edsdoj.bf3709bd973c499892bbf04526a3acf9
Document Type :
article
Full Text :
https://doi.org/10.3389/fimmu.2022.1027122